Tag Archives: ML6500

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023

February 23, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Light-induced drug delivery with indocyanine green liposomes

August 30, 2022 by Modulight Content
No comments
Introduction to light-controlled drug delivery systems Study description It is important that light-triggered liposomes efficiently release their contents, while the liposome stability should be maintained in the absence of laser light. The aim of this study is to determine how liposomal stability and drug release are affected by liposomal formulation. Indocyanine green was used as the light-sensitizing compound in the liposomes since it is clinically approved light-sensitive agent. Three different liposomal formulations were prepared: Formulation A: ICG in the aqueous core, liposomes coated Formulation B: ICG in the liposomal Continue reading →Customer case Faculty of Pharmacy at University of Helsinki is specialized in top-level pharmaceutical research. Multidisciplinary research fields include clinical pharmacy, experimental drugs, nanomedicines, and pharmaceutical drug design. Drug delivery unit led by Professor Arto Urtti focuses on design and testing of advanced drug delivery systems especially for ocular indications. Light is studied as an important tool to control the drug delivery to the target tissues. Modulight products: ML6600 (810 nm) + Modulight in vitro illumination kit (MLAKIT) Professor Arto Urtti   Senior Pharmaceutical Researcher Tatu Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2022

August 10, 2022 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – August 2022 Impressive research on head & neck cancer was published by Obaid Lab for molecular imaging and optical nanotherapeutics, at University of Texas, Dallas. The group used Modulight’s ML6500 for a subtherapeutic modulation of tumor microenvironment of H&N. This significantly improved delivery of molecular imaging agent to the tumors as well as improved diagnostic accuracy in detecting tumor tissue by fluorescence. Since incomplete resection and consequent recurrences are common problem with current H&N cancer treatment, this discovery answers unmet Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2022

July 11, 2022 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – July 2022 Modulight congratulates Dr. Makoto Mitsunaga et al. Jikei University School of Medicine for publishing their promising results in Communications Biology journal. The team developed a next-generation light-based approach to tackle pathogens, called photoimmuno-antimicrobial strategy (PIAS). This technology was shown to eliminate a broad spectrum of different classes of pathogens, such as viruses, fungi, and bacteria. Unlike antibiotics, PIAS was also effective against drug-resistant pathogens and didn’t damage natural, beneficial microbiota in the host’s tissues. As COVID-19 pandemic and Continue reading →

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW

June 28, 2022 by Modulight
No comments
Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid    Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid   The study showed that photodynamic priming (subtherapeutic doses of light using ML6500) of tumor microenvironment with nanoliposomal BPD is highly beneficial for delivery of antibodies (Cet-IR800) to H&N tumor in mice. Priming significantly improved the tumor accumulation of Cet-IR800 and diagnostic accuracy of tumor detection, as monitored with fluroescence imaging.   Read the article here

Modulight Spotlights: LASER-SHARP RESEARCH – February 2022

March 2, 2022 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – February 2022 Photocure’s blue light cystoscopy is a routine procedure in the management of bladder cancer as it results in better tumor visualization and removal. However, this study found that the positive effects of blue light cystoscopy could extend beyond visualization and result in the induction of systemic antitumor immunity, which can be further boosted with immune checkpoint inhibitors. Modulight nominated this study because bladder cancer is highly recurring and progressive disease with more than 200,000 deaths worldwide annually. Thus, Continue reading →

Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

February 25, 2022 by Modulight
No comments
Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya    Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya   Blue light cystoscopy/Photodynamic diagnosis (PDD) was shown in rat models of bladder cancer to not only help in visualization and better removal of tumors, but also lead to anti-tumor effects and stimulation of immune system. ML6500 was used as blue light source for PDD.   Read the article here

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →

Protected: New approach for targeted PDT of glioblastoma

August 17, 2021 by Modulight Content
No comments
There is no excerpt because this is a protected post.Customer case Research in close collaboration with University Medical Center Utrecht, Erasmus Medical Center and Leiden University Medical Center. Research focused on the efficacy and mechanisms of targeted cancer photoimmunotherapy using nanobodies (antibody fragments). The advantage of nanobodies lies in the combination of their small molecular size, with high binding affinity for their targets, resulting to high accumulation at the tumor site, better tumor penetration and faster clearance from blood circulation. The aim is to target therapy to cancer cell-expressing antigens like EGFR (H&N cancer) Continue reading →

Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →